

The Impact of Omics Technologies on Advancing Developmental Medicine

Naveed Shuja^{1*}

1- Departement of Biological Sciences, Lahore-UBAS (Lahore Medical & Dental College), Lahore, Pakistan.

*Corresponding Author: Naveed Shuja, Email: rananaveedshuja@gmail.com, Cell #: +92-3334205687

Keywords: Omics technologies, developmental medicine, genomics, transcriptomics, proteomics, metabolomics, precision medicine



Received: 08/05/2024

Revised: 17/07/2024

Accepted: 25/07/2024

Published: 31/07/2024

© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you must obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Omics technologies represent the emergence of a new paradigm in biomedical research and clinical practice and now enable us to understand human development and the molecular basis of developmental disorders[1]. Technologies such as genomics, transcriptomics, proteomics, metabolomics, and emerging fields such as epigenomics and microbiomics are transforming the revolution in our ability to decode the mysteries of health and disease in developmental medicine (a field of study that examines and treats children with congenital and developmental conditions)[2].

Genomics: Genomics is at the core of developmental medicine, the study of an organism's full genetic material[3]. Next-generation sequencing (NGS), whole genome sequencing (WGS), and whole exome sequencing (WES) have made dramatic improvements allowing for the better detection of genetic anomalies linked to developmental disorders. Mutations, including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and structural rearrangements, have been linked to conditions such as autism spectrum disorders (ASD), congenital heart defects, and neurodevelopmental delays [4].

Genomic breakthroughs give early, precise diagnoses for use in personalized therapeutic strategies. Early detection and treatment of inherited metabolic disorders by genetic screening in newborns and when neonates have developed clinical disorders are other examples of early detection and treatment. In addition, new disease pathways have been uncovered, and these can be targeted[5].

Transcriptomics: Genomics is when you get the blueprint and transcriptomics is when you get how and when to express the blueprint across developmental stages and tissues. RNA sequencing (RNA-seq) has established itself as a powerful tool for understanding temporal and spatial gene expression patterns and their molecular basis in developmental disorders. For instance, transcriptomic analysis has identified aberrant gene expression that is related to neurodevelopmental conditions, including epilepsy and cerebral palsy[6].

Single-cell RNA sequencing (scRNA-seq) is revolutionizing developmental biology and the ability to study gene expression at single-cell resolution. This technology is especially relevant in developmental medicine where cell lineage specification and cell-cell interactions determine organogenesis. For example, siRNA-seq has shown the developmental trajectories of neuronal and immune cells and the mechanisms of brain malformations [7].

Proteomics and Metabolomics: Analysis of the complete set of proteins and metabolites by proteomics and metabolomics, respectively, provides functional context to genomic and transcriptomic variations. Alterations in protein expression and post-translational modifications were demonstrated in proteomic studies in Duchenne muscular dystrophy (DMD) and mitochondrial disorders[8]. In contrast, metabolomics discovers biochemical perturbations that support developmental disorders. Metabolic profiling is used for the diagnosis and monitoring of inborn errors of metabolism such as

phenylketonuria (PKU). Further, metabolomics has been successfully integrated into noninvasive liquid biopsies, such as blood or saliva, to comprehensively monitor biomarkers of disease progression and treatment efficacy in pediatric populations.[9].

Epigenomics: Heritable modifications to DNA and histones that control gene activity while leaving the underlying genetic code intact are the province of epigenomics. Environmental factors such as maternal health, nutrition, and toxins have a pivotal role in the development of these modifications.

Several developmental disorders including Beckwith Wiedemann syndrome and Rett syndrome have been linked to DNA methylation and histone modifications. Prenatal stressors and environmental exposures are emerging as contributors to the shaping of epigenetic patterns during critical developmental windows, with lifelong health consequences[10].

Microbiomics: Gut microbiota and the human microbiome have been regularly targeted for their function in early development, immune system maturation, and neurodevelopment. The gut brain axis is disrupted in developmental disorders, e.g. autism spectrum disorders and GI dysregulation in children.

High-throughput sequencing-based microbiomics and multi-omics integration provide new insights into the impact of microbial communities on host metabolism, immune functioning, and cognitive development. Promising clinical applications include targeted probiotic therapies and dietary interventions to restore microbiome balance[11].

Multi-Omics Integration: Towards Precision Medicine: It is possible to transform developmental medicine through the integration of multi-omics data (genomics, transcriptomics, proteomics, metabolomics, and epigenomics). Multi-omics approaches construct comprehensive molecular networks to gain a systems-level understanding of disease pathogenesis and developmental biology.

Liquid biopsies are a major tool for the implementation of multi-omics analyses in clinical practice. These non-invasive samples enable the simultaneous analysis of circulating DNA, RNA, proteins, and metabolites, offering real-time views of disease progression and therapeutic responses. In pediatric care, early intervention is key to improving outcomes making such precision approaches particularly relevant[12].

Challenges and future directions: While omics technologies have the potential to be transformative to developmental medicine, several hurdles prevent their full integration into this field. High costs, complexity of data analysis, and the requirement for standard protocols for sample collection and bioinformatics workflows are included among these. Moreover, whereas omics discoveries need to be validated in large diverse cohorts for translation into actionable clinical outcomes,

qualitative cost analyses reveal that they potentially present the most opportunities for translating research findings to clinical practice.

There's much we can do to solve these problems with artificial intelligence (AI) and machine learning. Tools powered by AI can analyze complex multi-omics datasets and identify biomarkers, predict disease trajectories, and identify new therapeutic targets with unprecedented precision and speed[13].

CONCLUSION

Omics technologies are revolutionizing developmental medicine, allowing for a depth understanding of the genetic molecular, and environmental causes of health and disease. By empowering early diagnosis, precision therapies, and a greater understanding of developmental disorders, these tools are enabling improved clinical outcomes and healthier lives for children going forward.

To realize this potential, it will be necessary to sustain investment in research, technology, and clinical integration. As omics-driven discoveries, precision medicine, and technological innovation continue to converge, we look forward to a bright future where omics will transform the landscape of pediatric care by allowing us to diagnose, treat, and prevent developmental disorders in the next generation.

Funding: No funding was received

Conflict of interest: The author declared no conflict of interest.

Acknowledgement: I thank all contributors to the advancement of omics technologies in developmental medicine.

Authors contribution: Editorial was prepared by Dr. Naveed Shuja.

REFERENCES

1. Kim DH, Kim YS, Son NI, Kang CK, Kim AR. Recent omics technologies and their emerging applications for personalised medicine. *IET Syst Biol.* 2017;11(3):87-98. doi:10.1049/iet-syb.2016.0016
2. Dai X, Shen L. Advances and trends in omics technology development. *Front Med (Lausanne).* 2022;9:911861. doi:10.3389/fmed.2022.911861
3. Magro D, Venezia M, Balistreri CR. The omics technologies and liquid biopsies: advantages, limitations, applications. *Med Omics.* 2024;11:100039. doi:10.1016/j.meomic.2024.100039
4. Neumann E, Schreeck F, Herberg J, Jacqz Aigrain E, Maitland-van der Zee AH, Pérez-Martínez A, et al. How paediatric drug development and use could benefit from omics: a c4c expert group white paper. *Br J Clin Pharmacol.* 2022;88(12):5017-33. doi:10.1111/bcp.15216
5. Yan SK, Liu RH, Jin HZ, Liu XR, Ye J, Shan L, et al. Omics in pharmaceutical research: overview, applications, challenges, and future perspectives. *Chin J Nat Med.* 2015;13(1):3-21. doi:10.1016/S1875-5364(15)60002-4
6. McColl ER, Asthana R, Paine MF, Piquette-Miller M. The age of omics-driven precision medicine. *Clin Pharmacol Ther.* 2019;106(3):477-81. doi:10.1002/cpt.1532

7. Kim DH, Kim YS, Son N, Kang CK, Kim AR. Recent omics technologies and their emerging applications for personalized medicine. *IET Syst Biol.* 2017;11:—. doi:10.1049/iet-syb.2016.0016 (duplicate of #1 but retained as you listed)
8. Huzair F, Borda-Rodriguez A. Challenges for the application and development of omics health technologies in developing countries. *Drug Dev Res.* 2012;73:447-51. doi:10.1002/ddr.21036
9. Vogeser M, Bendt AK. From research cohorts to the patient—A role for omics in diagnostics and laboratory medicine? *Clin Chem Lab Med.* 2023;61(6):974-80. doi:10.1515/cclm-2022-1147
10. Nice EC. Challenges for omics technologies in personalized medicine. *Expert Rev Precis Med Drug Dev.* 2018;3(4):229-31. doi:10.1080/23808993.2018.1505429
11. Theodorakis N, Feretzakis G, Tzelvels L, Paxinou E, Hitas C, Vamvakou G, et al. Integrating machine learning with multi-omics technologies in geroscience: towards personalized medicine. *J Pers Med.* 2024;14(9):931. doi:10.3390/jpm14090931
12. Colin E, Duffourd Y, Tisserant E, Relator R, Bruel AL, Tran Mau-Them F, et al. OMIXCARE: omics technologies solved ~33% of heterogeneous rare neurodevelopmental disorders with negative exome results. *Front Cell Dev Biol.* 2022;10:1021785. doi:10.3389/fcell.2022.1021785
13. Aicher JK, Jewell P, Vaquero-Garcia J, Barash Y, Bhoj EJ. Mapping RNA splicing variations to improve Mendelian disease diagnosis using RNA-seq. *Genet Med.* 2020;22(7):1181-90. doi:10.1038/s41436-020-0780-y

This Article May be cited as: Shuja N. The impact of omics technologies on advancing developmental medicine: multi-omics integration. *Dev Med Life Sci.* 2024;1(5):1-4. doi:10.69750/dmls.01.05.082.

Publisher's Note:

Developmental Medico-Life-Sciences remains neutral with regard to jurisdictional claims in published maps. and institutional affiliations.

